<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cerebrotendinous xanthomatosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cerebrotendinous xanthomatosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cerebrotendinous xanthomatosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy T Waldman, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francisco González-Scarano, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cerebrotendinous xanthomatosis (CTX; MIM 213700) is an autosomal recessive lipid storage disease caused by disruption of bile acid synthesis that was first described in 1937 [<a href="#rid1">1</a>]. A deficiency of the enzyme sterol 27-hydroxylase causes the accumulation of cholesterol and cholestanol in virtually all tissues [<a href="#rid2">2</a>]. Fat deposition leads to the formation of xanthomas, nodules, and plaques in the central nervous system, eyes, tendons, skin, lungs, and bones.</p><p>CTX is one of a group of neurologic disorders, collectively referred to as leukodystrophies, which predominantly affect the central nervous system white matter. These disorders are caused by defects in the synthesis or maintenance of the myelin sheath that insulates the nerves.</p><p>The main neurologic features of CTX are cerebellar ataxia, pyramidal tract signs, and intellectual decline. One or more of these is usually apparent by late childhood or early adulthood. The syndrome is slowly progressive, and while there is no cure, its course can be altered with treatment.</p><p>This topic will review the pathogenesis, clinical features, diagnosis, and treatment of CTX.</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of cerebrotendinous xanthomatosis (CTX) involves a genetic defect in the <em>CYP27A1</em> gene that causes derangements of lipid metabolism.</p><p class="headingAnchor" id="H3"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>CTX is caused by pathogenic variants in the <em>CYP27A1</em> gene on chromosome 2q35 that encodes the mitochondrial enzyme sterol 27-hydroxylase [<a href="#rid3">3,4</a>]. Deficiency of this enzyme, a member of the cytochrome P-450 enzyme family, results in increased cholestanol and cholesterol.</p><p>Over 100 pathogenic variants have been described in <em>CYP27A1 </em>[<a href="#rid5">5</a>]. No correlation between genotype and phenotype has been established, even within identical twins and other family members [<a href="#rid6">6,7</a>]. </p><p>Inheritance of CTX is autosomal recessive.</p><p class="headingAnchor" id="H4"><span class="h2">Lipid derangements</span><span class="headingEndMark"> — </span>The normal catabolism of cholesterol depends on the formation of primary bile acids (cholic acid and <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a>) through various sterol intermediates. Ten different enzymes are required for the hydroxylation of the four-membered cholesterol ring structure in the endoplasmic reticulum and cytosol, and oxidation of its eight-carbon side chain in the mitochondria and peroxisomes [<a href="#rid8">8-11</a>].</p><p>Sterol 27-hydroxylase, in the presence of cofactors ferredoxin and NADPH-ferredoxin reductase, catalyzes the hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha, 12 alpha-triol at C27 [<a href="#rid3">3</a>]. The deficiency of sterol 27-hydroxylase leads to the accumulation of cholestanol and cholesterol and their precursors in plasma and tissues and the excretion of glucuronides in urine [<a href="#rid12">12</a>].</p><p>The disruption of bile acid synthesis in CTX leads to the upregulation of <em>CYP7A</em>, the gene encoding cholesterol 7 alpha-hydroxylase, which catalyzes the rate-limiting step of bile acid synthesis, the conversion of cholesterol and 7 alpha-hydroxycholesterol to cholestanol [<a href="#rid13">13</a>].</p><p>Hydrophobic bile acids are required to activate heterodimers that, in turn, reduce <em>CYP7A</em> transcription. However, in CTX, levels of <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a>, which is highly hydrophobic, are decreased [<a href="#rid14">14-16</a>]. In fact, the exogenous administration of chenodeoxycholic acid has been shown to downregulate <em>CYP7A</em> transcription [<a href="#rid17">17</a>].</p><p>Bile acids are also necessary for feedback inhibition of hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA), which is involved in regulating cholesterol production [<a href="#rid15">15</a>]. In CTX, increased activity of hepatic HMG-CoA reductase causes elevated synthesis of cholesterol, thereby enhancing hepatic secretion of apo B-containing lipoproteins. Low-density lipoprotein (LDL) receptors are upregulated, resulting in normal serum cholesterol levels in CTX [<a href="#rid18">18-20</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Neurologic injury</span><span class="headingEndMark"> — </span>Although the pathogenesis remains unknown, one hypothesis is that a membrane defect causes the accumulation of sterols in the eyes (blood-lens barrier), central nervous system (CNS) (blood-brain barrier), peripheral nerves (blood-nerve barrier), and vessel walls (endothelial cell membrane) [<a href="#rid21">21</a>].</p><p>In human aortic and pulmonary endothelium, sterol 27-hydroxylase may provide local defense against the accumulation of cholesterol in the arterial wall [<a href="#rid22">22</a>]. Cholesterol is a major constituent of the myelin sheath, and its availability in oligodendrocytes is a rate-limiting factor for brain maturation [<a href="#rid23">23</a>]. Cholesterol is also present in the plasma membranes of astrocytes and neurons [<a href="#rid24">24</a>]. Furthermore, sterols are important in membrane permeability. Minor changes in sterol structure, such as the incorporation of cholestanol instead of cholesterol, can have deleterious effects on cell membrane integrity [<a href="#rid24">24</a>].</p><p>Cholestanol is thought to be responsible for the neurologic toxicity in CTX. Evidence of a neurotoxic mechanism is supported by the finding of cholestanol deposition in neuronal cells, most notably Purkinje cells, in the cerebellum of rats fed a 1 percent cholestanol diet [<a href="#rid25">25</a>]. Furthermore, in vitro study of cerebellar neuronal cells cultured with cholestanol revealed increased apoptosis [<a href="#rid25">25</a>].</p><p>Additional evidence supporting a neurotoxic mechanism comes from a study of 12 patients with CTX who had magnetic resonance spectroscopy (MRS), which revealed decreased N-acetylaspartate (NAA), increased lactate, and normal choline [<a href="#rid14">14</a>]. Decreased NAA is thought to be due to neuronal or axonal damage, and increased lactate is a marker for a defect in mitochondrial metabolism or infiltration of inflammatory cells. The normal choline levels argue against processes that cause membrane breakdown, such as active demyelination.</p><p class="headingAnchor" id="H6"><span class="h2">Mitochondrial dysfunction</span><span class="headingEndMark"> — </span>As just discussed, the finding of increased lactate on MRS suggests diffuse brain mitochondrial dysfunction in patients with CTX [<a href="#rid14">14</a>]. In addition, abnormal aggregates of mitochondria were observed in muscle biopsies performed in eight patients with CTX [<a href="#rid26">26</a>]. An additional case had decreased activity of respiratory chain enzymes, including cytochrome c oxidase, as well as significantly elevated pyruvate and lactate in the serum and cerebrospinal fluid [<a href="#rid27">27</a>]. Clinically, the patient had a myopathic facies (ie, expressionless with drooping cheeks and inability to smile or frown due to weakness) and generalized muscle weakness, consistent with mitochondrial dysfunction.</p><p>The cause of the mitochondrial dysfunction remains unknown, but one hypothesis is that toxic effects of elevated cholestanol or bile acids or membrane alteration may play a role.</p><p class="headingAnchor" id="H7"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cerebrotendinous xanthomatosis (CTX) is a rare disease with variable penetrance based upon ancestry. The disease has been reported in numerous countries around the world [<a href="#rid14">14,21,28-33</a>]. The highest estimated prevalence (approximately 8.6 per 100,000) has been reported in Jews of Moroccan origin and the Druze in Israel, where active genetic screening programs exist [<a href="#rid34">34-36</a>]. The estimated prevalence of CTX is 3 to 5 per 100,000 in White Americans [<a href="#rid7">7</a>]. </p><p>In a 2015 study using exome data (approximately 60,000 samples) and bioinformatics, the estimated incidence of CTX in Americans was between 1:71,677 and 1:148,914, a range more frequent than previously reported [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Many systemic and neurologic symptoms have been identified in patients with cerebrotendinous xanthomatosis (CTX), including intractable diarrhea, premature cataracts, tendon xanthomas, and progressive neurologic signs and symptoms [<a href="#rid38">38</a>]. The systemic features typically present earlier than the neurologic manifestations but CTX is not always recognized in these individuals. The mean age at diagnosis ranges from 32 to 41 years (range 5 to 71 years), at a time when the neurologic symptoms are often present [<a href="#rid12">12,39,40</a>]. Clinicians must have a high index of suspicion in any individual with the key features listed below.</p><p>Neurologic dysfunction involving cerebral, cerebellar, neuropsychiatric, myelopathic, or peripheral manifestations is usually apparent by late childhood or early adulthood, and progresses during adulthood.</p><p class="headingAnchor" id="H9"><span class="h2">Systemic</span></p><p class="headingAnchor" id="H2319759333"><span class="h3">Jaundice and diarrhea</span><span class="headingEndMark"> — </span>Neonatal cholestatic jaundice is often the earliest symptom of CTX, but does not occur in every patient [<a href="#rid41">41</a>]. There is significant clinical heterogeneity, even among siblings with the same pathogenic <em>CYP27A1</em> variant. For some, the jaundice self-resolves; others require treatment with bile acids (see <a class="local">'Treatment'</a> below). Fetal demise and death in infancy have occurred in siblings of CTX patients, including one child with jaundice from birth until his death at 13 months, suggesting that <em>CYP27A</em> pathogenic variants may be fatal in some patients [<a href="#rid41">41</a>].</p><p>Chronic infantile diarrhea, which is due to a defect in bile acid synthesis, is another early symptom of CTX. However, hepatitis of infancy and chronic diarrhea are rarely identified as symptoms of CTX until other manifestations of the disease appear. These symptom are present in approximately 20 to 55 percent of affected individuals [<a href="#rid12">12,40,42</a>].</p><p class="headingAnchor" id="H2648924493"><span class="h3">Cataracts</span><span class="headingEndMark"> — </span>Most patients (75 percent) present to medical attention in the first decade of life because of cataracts [<a href="#rid2">2,43</a>], and the overall incidence of cataracts is 60 to 70 percent [<a href="#rid40">40,42</a>], although it may be as high as 92 percent [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Xanthomas</span><span class="headingEndMark"> — </span>Xanthomas develop in approximately 70 to 77 percent of patients with CTX [<a href="#rid12">12,42,44</a>]. They typically form in the second or third decade on the Achilles  (<a class="graphic graphic_figure graphicRef126692" href="/z/d/graphic/126692.html" rel="external">figure 1</a>), extensor elbow, extensor hand, patellar, and neck tendons. They begin as painless thickening of the tendon but as they grow, they can interfere with joint function [<a href="#rid45">45,46</a>]. Xanthomas can also develop in the brain, lungs, and bones.</p><p class="headingAnchor" id="H11"><span class="h3">Skeletal abnormalities</span><span class="headingEndMark"> — </span>Although serum calcium is normal, patients with CTX have skeletal abnormalities due to impaired calcium absorption (demonstrated by impaired radiocalcium uptake) that leads to decreased bone density/osteopenia, osteoporosis, and fractures [<a href="#rid45">45,47,48</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Cardiovascular</span><span class="headingEndMark"> — </span>Atherosclerosis and cardiovascular disease have been associated with CTX, including reports of premature coronary atheroma, angina pectoris, myocardial infarction, aneurysmal coronary artery disease, mitral valve insufficiency, and lipomatous hypertrophy of the atrial septum [<a href="#rid49">49-51</a>]. The true prevalence of cardiac disease in CTX is unknown, but in one review of 144 patients with CTX, cardiac abnormalities were found in 15 patients (10 percent) [<a href="#rid28">28</a>]. In a series of seven patients who were studied with myocardial scintigram and coronary angiography, asymptomatic coronary artery disease was present in four [<a href="#rid49">49</a>].</p><p>The most likely mechanism of cardiac disease and atherosclerosis in CTX is the accumulation of cholesterol and cholestanol in various tissues [<a href="#rid50">50</a>]. However, this relationship is controversial, in part because patients with CTX are more likely to have what looks like an "antiatherogenic" lipid profile, with lower total cholesterol and low-density lipoprotein (LDL) levels and increased high-density lipoprotein (HDL) levels, than controls [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Other</span><span class="headingEndMark"> — </span>Premature aging and hypothyroidism have also been reported in patients with CTX [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Neurologic</span><span class="headingEndMark"> — </span>Although intellectual disability can present in infancy, most patients with CTX have borderline or normal intelligence until puberty. Intellectual functioning worsens with age, and over 50 percent of individuals with CTX have dementia and intellectual decline in their 20s [<a href="#rid2">2</a>]. Approximately 74 percent ultimately have neurocognitive deficits [<a href="#rid12">12</a>]. Cholestanol induces apoptosis of neurons, including cerebellar Purkinje cells [<a href="#rid25">25,52-54</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Neuropsychiatric manifestations of CTX include paranoid delusions, hallucinations, agitation, aggression, and depression. The latter may lead to suicide attempts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many patients develop spasticity [<a href="#rid55">55</a>], which is especially prominent in spinal xanthomatosis. (See <a class="local">'Spinal variant'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures occur in approximately 50 percent of patients with CTX [<a href="#rid2">2</a>], and can be the presenting symptom [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extrapyramidal symptoms, such as parkinsonism, dystonia, myoclonus, and postural tremor, are observed in approximately 20 percent of patients [<a href="#rid58">58-62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both demyelinating and axonal neuropathies have been described [<a href="#rid63">63</a>], leading to distal muscle atrophy and pes cavus. Sensory symptoms are typically absent.</p><p></p><p>Neurologic symptoms are mostly secondary to a metabolic encephalopathy, not due to structural disease related to focal xanthomas [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Spinal variant</span><span class="headingEndMark"> — </span>A rare spinal variant of CTX is characterized by a slowly progressive myelopathy and corticospinal and dorsal column demyelination [<a href="#rid64">64-66</a>]. In the largest series, with seven patients, the age at presentation ranged from 20 to 35 years old, and all had juvenile bilateral cataracts [<a href="#rid64">64</a>]. Other typical features of CTX, such as diarrhea, xanthomas, dementia, ataxia, and polyneuropathies, were less frequent than cataracts. Only two patients developed the classic symptoms; these were detected five to eight years after the onset of the myelopathy. In general, patients with spinal xanthomatosis have a milder clinical course than those with classic CTX [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Neuroimaging</span><span class="headingEndMark"> — </span>Head computed tomography (CT) and magnetic resonance imaging (MRI) reveal diffuse atrophy, white matter signal alterations affecting cerebellum more than cerebrum, and bilateral focal cerebellar lesions [<a href="#rid67">67</a>].</p><p>On CT, white matter changes are hypodense, while cerebellar xanthomas are hyperdense.</p><p>In adults, hyperintense lesions on T2-weighted MRI are observed in the dentate nucleus  (<a class="graphic graphic_diagnosticimage graphicRef128092" href="/z/d/graphic/128092.html" rel="external">image 1</a>), globus pallidus, substantia nigra, and inferior olive [<a href="#rid68">68</a>]. With disease progression, these lesions typically extend into adjacent white matter  (<a class="graphic graphic_diagnosticimage graphicRef138749" href="/z/d/graphic/138749.html" rel="external">image 2</a>). On MRI, fluid-attenuated inversion recovery (FLAIR) sequences may be more sensitive than T2-weighted sequences, as suggested by a study of 12 patients with CTX that found bilateral hyperintensities in the dentate nuclei on T2 and FLAIR sequences in 9 and 12 patients, respectively [<a href="#rid14">14</a>]. As described above, cholestanol induces neuronal apoptosis; brain atrophy, particularly in the gray matter, is also evident on MRI [<a href="#rid54">54,61,69</a>].</p><p>Both dentate hyperintensity (common) and hypointensity (less common) on T2 MRI have been reported in CTX [<a href="#rid68">68</a>]. This discrepancy is explained by the presence of hemosiderin deposits and calcifications in the dentate, which lowers the T2 signal intensity.</p><p>The presence of bilateral focal cerebellar lesions and the predominance of cerebellar white matter involvement helps distinguish the radiographic features of CTX  (<a class="graphic graphic_diagnosticimage graphicRef138749" href="/z/d/graphic/138749.html" rel="external">image 2</a>) from other leukodystrophies  (<a class="graphic graphic_algorithm graphicRef65871" href="/z/d/graphic/65871.html" rel="external">algorithm 1</a>) [<a href="#rid67">67,70</a>]. </p><p>In a retrospective MRI study of 38 individuals with CTX, all had brain imaging abnormalities [<a href="#rid70">70</a>]. Among six patients with dentate nuclei hyperintense T2/FLAIR lesions and cerebellar vacuolation, five had progression of clinical disability and all six had worsening MRI scans; among six patients with dentate nuclei T2/FLAIR hyperintensity but without vacuolation, only one showed clinical worsening at follow-up, and MRI progression was absent or mild. The four patients without any dentate abnormalities on MRI remained clinically and neuroradiologically stable during follow-up.</p><p>In the spinal variant of CTX, abnormal signal on T2-weighted images was observed in the lateral and dorsal columns [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>The disruption of bile acid synthesis in CTX results in a number of laboratory abnormalities. Serum and tissue levels of cholestanol are elevated, frequently 5 to 10 times normal levels, whereas serum cholesterol levels are normal or decreased. Plasma values of cholestanol are normally less than 4 to 5.2 mg/L. Values from 8.5 to 100.6 mg/L have been reported in CTX [<a href="#rid12">12</a>]. The formation of <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a> is markedly decreased, and the bile, urine, and serum concentrations of bile alcohols and their glycoconjugates are increased.</p><p>Increased serum lactate is also seen, but this finding is nonspecific. Changes in the blood-brain barrier result in increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid.</p><p>While not routinely evaluated, the enzymatic activity of sterol 27-hydroxylase is markedly reduced in fibroblasts, liver, and leukocytes in patients with CTX.</p><p class="headingAnchor" id="H18"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Sections of gross brain from patients with CTX reveal symmetric lesions in the cerebellar white matter, globus pallidus, midbrain, posterior part of the internal capsule, and dentate nuclei [<a href="#rid68">68</a>]. Granulomatous and xanthomatous lesions are seen in the cerebellar hemispheres, globus pallidus, and cerebellar peduncles [<a href="#rid2">2</a>].</p><p>Microscopic examination reveals extensive rarefaction, with severe neuronal loss, demyelination, hemosiderin deposits, lipid crystal clefts, fibrosis, infiltration of foamy macrophages, and reactive astrocytosis [<a href="#rid68">68</a>]. The cerebellar findings of lipid crystal clefts, xanthomatous lesions, fibrosis, and hemosiderin deposits, especially around the dentate nuclei, are pathognomonic for cerebrotendinous xanthomatosis [<a href="#rid64">64,68</a>]. In addition to the typical brain pathology, patients with significant spinal cord involvement have extensive demyelination, axonal loss, gliosis, and macrophagic infiltrates in the corticospinal tracts and gracile tracts.</p><p>Microscopically, xanthomas have shown birefringent crystalline storage material surrounded by multinucleated giant cells with foamy cytoplasm [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H19"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cerebrotendinous xanthomatosis (CTX) is suggested when the typical symptoms are present. The presence of the hallmark clinical manifestations of CTX – chronic diarrhea, bilateral cataracts, tendon xanthomas, and neurologic dysfunction – should prompt further investigations [<a href="#rid7">7</a>]. Laboratory studies showing elevated levels of serum cholestanol and serum and urine bile alcohols are supportive of the diagnosis, and genetic testing can confirm the diagnosis. (See <a class="local">'Clinical features'</a> above.)</p><p>Suspicion for CTX is highest in patients with the following indicators [<a href="#rid2">2,39,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sibling with CTX</p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal cholestatic jaundice</p><p class="bulletIndent1"><span class="glyph">●</span>Infantile diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Noncongenital cataracts presenting in childhood</p><p class="bulletIndent1"><span class="glyph">●</span>Tendon xanthomas presenting during adolescence or early adulthood</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive neurologic dysfunction beginning in late childhood or early adulthood</p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia or spastic paraparesis</p><p class="bulletIndent1"><span class="glyph">●</span>Intellectual disability or psychiatric disturbances</p><p class="bulletIndent1"><span class="glyph">●</span>MRI evidence of dentate nuclei signal alterations</p><p class="bulletIndent1"><span class="glyph">●</span>Consanguineous parents</p><p></p><p>Thus, CTX should be considered if a child has prolonged neonatal jaundice or infantile diarrhea of unclear etiology, especially if there is a family history of similar symptoms or fetal demise. However, as noted earlier, hepatitis of infancy and chronic diarrhea are rarely identified as symptoms of CTX until other manifestations of the disease appear. In patients with intellectual disability who have a component of progressive neurologic disease, CTX deserves special consideration because of its response to treatment.</p><p>While CTX is suggested by the presence of xanthomas and cholesterol abnormalities, it may not be considered in patients lacking these systemic findings. However, this may lead to diagnostic error, as one review found that xanthomas were not present in 29 percent of patients with CTX [<a href="#rid44">44</a>]. In addition, children with early-stage CTX may present with bile disorders, diarrhea, or cataracts, but may lack overt neurologic symptoms or signs. In such cases, laboratory testing for serum cholestanol and serum and urine bile alcohols should be performed [<a href="#rid71">71</a>]. The strategy of screening for elevated urine bile alcohols has been successful in recognizing CTX even when it was not clinically suspected [<a href="#rid72">72</a>]; however, such screening is not routinely performed.</p><p>The presence of bilateral neuroimaging abnormalities in the dentate nuclei of the cerebellum strongly supports the diagnosis of CTX in patients who have clinical features that raise suspicion for the disorder.</p><p>Molecular genetic testing including sequence analysis can detect pathogenic <em>CYP27A1</em> variants in up to 99 percent of affected individuals [<a href="#rid2">2</a>]. Genetic testing with sequence analysis is clinically available and is suggested to confirm the diagnosis.</p><p class="headingAnchor" id="H20"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>In patients with neurologic disease, myotonic dystrophy is the number one cause of early-onset cataracts, followed by CTX [<a href="#rid73">73</a>]. Distal myotonic dystrophy, as opposed to the proximal and neonatal forms, presents as early as adolescence with impaired muscle relaxation after contraction, facial and distal limb weakness, cataracts, frontal baldness, and endocrine abnormalities. The characteristic myotonia of myotonic dystrophy, which may be confirmed by clinical examination and/or by electromyography, should readily differentiate myotonic dystrophy from CTX. (See  <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis"</a>.)</p><p>Tendon xanthomas are also present in sitosterolemia, an inherited sterol storage disease. However, neurologic signs and cataracts are absent [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a>.)</p><p>Similarly, xanthomas affecting the spinal cord may lead to spastic paraparesis in the absence of other features of CTX. While hypercholesterolemia and hyperlipidemia cause xanthomas, serum concentrations of cholestanol are normal.</p><p>A minority of patients with Langerhans cell histiocytosis have central nervous system involvement with ataxia, behavioral change, cognitive dysfunction, and bilateral symmetric lesions on brain MRI in the dentate nucleus of the cerebellum or in basal ganglia. The presentation may mimic CTX [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Central nervous system'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The mainstay of treatment for cerebrotendinous xanthomatosis (CTX) is <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a>. Although unproven, treatment with statins may be beneficial, but only when combined with chenodeoxycholic acid.</p><p>There are limited and conflicting data regarding the clinical benefit with low-density lipoprotein (LDL) apheresis [<a href="#rid69">69,76-78</a>].</p><p>Symptomatic therapies are also important.</p><p class="headingAnchor" id="H22"><span class="h2">Chenodeoxycholic acid</span><span class="headingEndMark"> — </span>In 1975, <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a> (CDCA) was shown to decrease cholesterol synthesis [<a href="#rid18">18</a>]. In the decades since, CDCA has remained the treatment of choice for CTX because it can stabilize or possibly reverse some of the associated symptoms.</p><p>We recommend treatment with CDCA for children and adults with CTX. The usual dose of CDCA is 250 mg three times a day for adults and 15 mg/kg per day in three divided doses for children; lower doses may be less effective [<a href="#rid12">12</a>]</p><p>In the first prospective (nonblinded) treatment study, 17 symptomatic patients with CTX were given CDCA, 750 mg daily [<a href="#rid29">29</a>]. After at least one year of treatment, the following observations were made:</p><p class="bulletIndent1"><span class="glyph">●</span>Dementia cleared in 10 of 13 patients</p><p class="bulletIndent1"><span class="glyph">●</span>Pyramidal tract and cerebellar signs disappeared in five</p><p class="bulletIndent1"><span class="glyph">●</span>Electroencephalographic abnormalities resolved in 5 of 10 patients</p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral CT scans improved in seven patients, and one cerebellar xanthoma disappeared</p><p class="bulletIndent1"><span class="glyph">●</span>Mean serum cholestanol levels declined by a factor of three, and abnormal bile acid synthesis was suppressed</p><p></p><p>In a larger retrospective study of 43 patients with CTX, 31 were taking CDCA [<a href="#rid12">12</a>]. The patients were followed for a mean of 8 years. CDCA treatment was associated with improvement in symptoms in 57 percent, disease stabilization in 23 percent, and disease progression in 20 percent. All of the patients who worsened on CDCA were over 25 years of age and had significant neurologic symptoms at the time of diagnosis; some were treated with a lower dose of CDCA due to elevated liver enzymes or had an interruption in therapy due to drug availability. The mean pretreatment cholestanol level was 32 mg/L, and the post-treatment level was 6 mg/L, an 81 percent reduction on CDCA. The plasma cholestanol levels normalized in 63 percent of patients. </p><p>In adults with CTX, long-term treatment with CDCA (250 mg orally three times daily) corrects the defect of bile acid metabolism and normalizes the serum, urine, and cerebrospinal fluid lipid concentrations. Despite these data, the neurologic and psychiatric symptoms are often difficult to treat, and, if advanced, may not improve with CDCA [<a href="#rid79">79-81</a>]. CDCA may not reverse tendon xanthomas or cataracts [<a href="#rid7">7,29,79</a>]. </p><p>Starting CDCA during childhood or young adulthood may be associated with greater benefit than starting treatment in older adults, when irreversible neurologic injury may be present [<a href="#rid81">81-84</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of five symptomatic children (ages 7 to 20 years) treated with CDCA (15 mg/kg per day in three divided doses), diarrhea resolved immediately with the start of treatment, and biochemical abnormalities normalized [<a href="#rid82">82</a>]. At one year, no further motor development delays were observed, and the intelligence quotient improved in three children. At five years after the start of CDCA, the children were reported as in stable clinical condition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another report described four patients with CTX within one family who were treated with CDCA for 14 years [<a href="#rid83">83</a>]. At the time treatment was started, two young sisters had minimal symptoms and two older brothers (uncles of the sisters) were already severely affected. After 14 years of follow-up, the two sisters remained free of symptoms, whereas the two uncles experienced only moderate improvement in symptoms. </p><p></p><p class="headingAnchor" id="H23"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>There are few data regarding adverse effects of CDCA in patients with CTX. However, in patients with gallstones who are treated with CDCA, dose-related diarrhea is seen in approximately 50 percent, and hypercholesterolemia and increased serum aminotransferases are observed in a substantial proportion. Since diarrhea is a common feature of CTX, it is not clear whether CDCA causes or exacerbates diarrhea in patients with CTX.</p><p>Plasma cholestanol levels may be monitored for drug efficacy (although it may take up to two years to normalize) and drug adherence [<a href="#rid7">7</a>]. Liver enzymes should be followed regularly and were elevated in 9 percent of adults on CDCA therapy in one study [<a href="#rid12">12</a>]. While elevated liver enzymes are often asymptomatic, the dose of CDCA may be reduced if signs of hepatotoxicity develop. One infant developed jaundice, pruritus, and hepatomegaly six weeks after initiation of therapy that resolved on a CDCA dose of 5 mg/kg/day [<a href="#rid85">85</a>]. For this patient, plasma cholestanol levels normalized on the lower dose.</p><p>Routine measurement of lipids and fat-soluble vitamins (given the diarrhea) is not necessary but rather should follow clinical guidelines and symptoms.</p><p class="headingAnchor" id="H1889765200"><span class="h3">Pregnancy and CDCA</span><span class="headingEndMark"> — </span>Observational studies have reported that women taking CDCA have conceived and delivered healthy children, while those not taking CDCA have had difficulty conceiving, pregnancies complicated by miscarriages or stillbirths, and children with intellectual disability [<a href="#rid7">7,41,44,81,86</a>].</p><p class="headingAnchor" id="H2895225621"><span class="h2">Cholic acid</span><span class="headingEndMark"> — </span>While cholic acid has been used a treatment for CTX in a few cases [<a href="#rid87">87,88</a>], high-quality data on long-term efficacy and safety are not available. Cholic acid is approved by the US Food and Drug Administration (FDA) for the treatment of bile acid disorders cause by single acid defects. The bile acids in CTX cannot be broken down to CDCA and cholic acid in the absence of <em>CYP27A1</em>; thus, exogenous administration of cholic acid is expected to result in decreased accumulation of cholestanol through feedback inhibition. Note that patients with CTX have relatively normal levels of cholic acid due a different enzymatic pathway [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H24"><span class="h2">Statins</span><span class="headingEndMark"> — </span>Statins lower cholesterol and have been studied as a treatment for CTX [<a href="#rid27">27,71</a>]. However, statins deplete CoQ10 and thereby alter mitochondrial function, which is a theoretical concern because abnormal mitochondrial metabolism has been reported in CTX. (See <a class="local">'Mitochondrial dysfunction'</a> above.)</p><p>Although data are sparse, statin monotherapy appears to have little or no benefit for CTX. However, statins may be useful for lowering cholestanol levels when combined with CDCA, especially if CDCA treatment monotherapy is not effective in lowering cholestanol levels [<a href="#rid17">17,78,89-91</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Symptomatic therapies</span><span class="headingEndMark"> — </span>Management of CTX may require interventions for cataracts, epilepsy, parkinsonism, and spasticity. Patients often require cataract surgery before the age of 50 [<a href="#rid2">2,43</a>]. There is evidence from one small study that cerebellar ataxia may improve with piracetam (not available in the United States) [<a href="#rid92">92</a>]. Seizure frequency may improve with CDCA, allowing a decrease in the number of antiseizure medications or monotherapy dose [<a href="#rid93">93</a>].</p><p>Xanthomas that interfere with joint function may be surgically excised [<a href="#rid45">45</a>].</p><p>Management of seizures and epilepsy is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">"Seizures and epilepsy in children: Initial treatment and monitoring"</a>.)</p><p>Levodopa/<a class="drug drug_general" data-topicid="9200" href="/z/d/drug information/9200.html" rel="external">carbidopa</a> has been used to treat the parkinsonian symptoms of CTX with variable success [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H530691464"><span class="h2">Prognosis and future directions</span><span class="headingEndMark"> — </span>CTX is progressive without treatment, with possible survival into the fifth or sixth decades. Early treatment is critical in delaying or alleviating many of the symptoms. Thus, newborn screening programs have been piloted with success [<a href="#rid52">52,95,96</a>]. The implementation of such programs, especially in high-frequency populations, is likely to alter the morbidity and mortality of this disease.</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebrotendinous xanthomatosis (CTX) is a rare disease caused by a genetic defect in the <em>CYP27A1</em> gene, which results in a deficiency of sterol 27-hydroxylase, with accumulation of cholesterol and cholestanol in virtually all tissues. Cholestanol is thought to be responsible for the neurologic toxicity in CTX. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms associated with CTX include intractable diarrhea, premature cataracts, tendon xanthomas, premature atherosclerosis, and cardiovascular disease. The systemic features typically present earlier than the neurologic manifestations. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic dysfunction, including intellectual disability, dementia, epilepsy, parkinsonism, myelopathy, and neuropathy, is usually apparent by late childhood or early adulthood, and progresses during adulthood. (See <a class="local">'Neurologic'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Head computed tomography (CT) and brain magnetic resonance imaging (MRI) reveal diffuse atrophy, white matter signal alterations affecting cerebellum more than cerebrum, and bilateral focal cerebellar lesions. Hyperintense lesions on T2-weighted and fluid-attenuated inversion recovery (FLAIR) MRI are observed in the dentate nucleus, globus pallidus, substantia nigra, and inferior olive. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum and tissue levels of cholestanol are elevated to 5 to 10 times normal levels, whereas serum cholesterol levels are normal or decreased. The formation of <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a> is markedly decreased, and the bile, urine, and serum concentrations of bile alcohols and their glycoconjugates are increased. (See <a class="local">'Laboratory'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of CTX is suggested by the typical constellation of CTX symptoms, which are seen in most patients with the disorder. These symptoms are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal cholestatic jaundice</p><p class="bulletIndent2"><span class="glyph">•</span>Infantile diarrhea</p><p class="bulletIndent2"><span class="glyph">•</span>Noncongential cataracts presenting in childhood</p><p class="bulletIndent2"><span class="glyph">•</span>Tendon xanthomas presenting during adolescence or early adulthood</p><p class="bulletIndent2"><span class="glyph">•</span>Progressive neurologic dysfunction beginning in late childhood or early adulthood</p><p></p><p class="bulletIndent1">Elevated levels of serum cholestanol and serum and urine bile alcohols are supportive of the diagnosis, which can be confirmed with genetic testing. Laboratory testing for serum cholestanol and serum and urine bile alcohols should be performed for children with bile disorders, diarrhea, or cataracts. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children and adults with CTX, we recommend treatment with <a class="drug drug_general" data-topicid="15546" href="/z/d/drug information/15546.html" rel="external">chenodeoxycholic acid</a> (CDCA) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The suggested dose of CDCA is 250 mg three times a day for adults, and 15 mg/kg per day in three divided doses for children. It is important to begin treatment before the onset of neurologic dysfunction in order to prevent irreversible neuronal injury; clinical improvement in established disease is uncommon. (See <a class="local">'Chenodeoxycholic acid'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">van Bogaert L, Schere H, Epstein E. Une forme cérébrale de la cholestérinose généralisée, Masson et Cie, Paris 1937.</li><li class="breakAll">Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1409/ (Accessed on July 18, 2019).</li><li><a class="nounderline abstract_t">Leitersdorf E, Reshef A, Meiner V, et al. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. J Clin Invest 1993; 91:2488.</a></li><li><a class="nounderline abstract_t">Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991; 266:7779.</a></li><li class="breakAll">The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. www.hgmd.cf.ac.uk/ac/ (Accessed on December 04, 2018).</li><li><a class="nounderline abstract_t">Zádori D, Szpisjak L, Madar L, et al. Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series. Neurol Sci 2017; 38:481.</a></li><li><a class="nounderline abstract_t">Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis 2017; 40:771.</a></li><li><a class="nounderline abstract_t">Ohno T, Kobayashi S, Hayashi M, et al. Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci 2001; 182:95.</a></li><li><a class="nounderline abstract_t">Andersson S, Davis DL, Dahlbäck H, et al. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem 1989; 264:8222.</a></li><li><a class="nounderline abstract_t">Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 1991; 266:7774.</a></li><li><a class="nounderline abstract_t">Björkhem I, Hansson M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem Biophys Res Commun 2010; 396:46.</a></li><li><a class="nounderline abstract_t">Duell PB, Salen G, Eichler FS, et al. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. J Clin Lipidol 2018; 12:1169.</a></li><li><a class="nounderline abstract_t">Crestani M, Sadeghpour A, Stroup D, et al. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J Lipid Res 1998; 39:2192.</a></li><li><a class="nounderline abstract_t">De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 2001; 124:121.</a></li><li class="breakAll">Björkhem I, Boberg KM. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. In: The metabolic and molecular basis of inherited disease, Scriver C, Beaudet AL, Sly WS, et al (Eds), McGraw-Hill, New York 1995. Vol 7, p.2273.</li><li class="breakAll">Federico A, Dotti MT. Cerebrotendinous xanthomatosis. In: Handbook of clinical neurology, Vinken PJ, Bruyn GW, Moser HW (Eds), Elsevier Science, Amsterdam 1996. Vol 66, p.599.</li><li><a class="nounderline abstract_t">Batta AK, Salen G, Tint GS. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. Metabolism 2004; 53:556.</a></li><li><a class="nounderline abstract_t">Salen G, Meriwether TW, Nicolau G. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med 1975; 14:57.</a></li><li><a class="nounderline abstract_t">Ballantyne CM, Vega GL, East C, et al. Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism 1987; 36:270.</a></li><li><a class="nounderline abstract_t">Tint GS, Ginsberg H, Salen G, et al. Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis. J Lipid Res 1989; 30:633.</a></li><li><a class="nounderline abstract_t">Verrips A, Hoefsloot LH, Steenbergen GC, et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123 ( Pt 5):908.</a></li><li><a class="nounderline abstract_t">Reiss AB, Martin KO, Rojer DE, et al. Sterol 27-hydroxylase: expression in human arterial endothelium. J Lipid Res 1997; 38:1254.</a></li><li><a class="nounderline abstract_t">Saher G, Brügger B, Lappe-Siefke C, et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005; 8:468.</a></li><li><a class="nounderline abstract_t">Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004; 24:806.</a></li><li><a class="nounderline abstract_t">Inoue K, Kubota S, Seyama Y. Cholestanol induces apoptosis of cerebellar neuronal cells. Biochem Biophys Res Commun 1999; 256:198.</a></li><li><a class="nounderline abstract_t">Federico A, Dotti MT, Volpi N. Muscle mitochondrial changes in cerebrotendinous xanthomatosis. Ann Neurol 1991; 30:734.</a></li><li><a class="nounderline abstract_t">Dotti MT, Manneschi L, Federico A. Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. J Neurol Sci 1995; 129:106.</a></li><li><a class="nounderline abstract_t">Kuriyama M, Fujiyama J, Yoshidome H, et al. Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. J Neurol Sci 1991; 102:225.</a></li><li><a class="nounderline abstract_t">Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984; 311:1649.</a></li><li><a class="nounderline abstract_t">Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. Clin Neurol Neurosurg 1987; 89:169.</a></li><li><a class="nounderline abstract_t">Farpour H, Mahloudji M. Familial cerebrotendinous xanthomatosis. Report of a new family and review of the literature. Arch Neurol 1975; 32:223.</a></li><li><a class="nounderline abstract_t">Ben Hamida M, Chabbi N, Ben Hamida C, et al. [Peripheral neuropathy in a sporadic case of cerebrotendinous xanthomatosis]. Rev Neurol (Paris) 1991; 147:385.</a></li><li><a class="nounderline abstract_t">Ko KF, Lee KW. Cerebrotendinous xanthomatosis in three siblings from a Chinese family. Singapore Med J 2001; 42:30.</a></li><li><a class="nounderline abstract_t">Berginer VM, Abeliovich D. Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccan origin. Am J Med Genet 1981; 10:151.</a></li><li><a class="nounderline abstract_t">Falik-Zaccai TC, Kfir N, Frenkel P, et al. Population screening in a Druze community: the challenge and the reward. Genet Med 2008; 10:903.</a></li><li><a class="nounderline abstract_t">Rosner G, Rosner S, Orr-Urtreger A. Genetic testing in Israel: an overview. Annu Rev Genomics Hum Genet 2009; 10:175.</a></li><li><a class="nounderline abstract_t">Appadurai V, DeBarber A, Chiang PW, et al. Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes. Mol Genet Metab 2015; 116:298.</a></li><li><a class="nounderline abstract_t">Degos B, Nadjar Y, Amador Mdel M, et al. Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood. Orphanet J Rare Dis 2016; 11:41.</a></li><li><a class="nounderline abstract_t">Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. J Inherit Metab Dis 2014; 37:421.</a></li><li><a class="nounderline abstract_t">Sekijima Y, Koyama S, Yoshinaga T, et al. Nationwide survey on cerebrotendinous xanthomatosis in Japan. J Hum Genet 2018; 63:271.</a></li><li><a class="nounderline abstract_t">Clayton PT, Verrips A, Sistermans E, et al. Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 2002; 25:501.</a></li><li><a class="nounderline abstract_t">Wong JC, Walsh K, Hayden D, Eichler FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis 2018; 41:647.</a></li><li><a class="nounderline abstract_t">Cruysberg JR, Wevers RA, van Engelen BG, et al. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. Am J Ophthalmol 1995; 120:597.</a></li><li><a class="nounderline abstract_t">Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004; 27:42.</a></li><li><a class="nounderline abstract_t">Sasamura A, Akazawa S, Haraguchi A, et al. Late-onset Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene. Intern Med 2018; 57:1611.</a></li><li><a class="nounderline abstract_t">Chen C, Zhang Y, Wu H, et al. Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families. Metab Brain Dis 2017; 32:1609.</a></li><li><a class="nounderline abstract_t">Berginer VM, Shany S, Alkalay D, et al. Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 1993; 42:69.</a></li><li><a class="nounderline abstract_t">Federico A, Dotti MT, Loré F, Nuti R. Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci 1993; 115:67.</a></li><li><a class="nounderline abstract_t">Fujiyama J, Kuriyama M, Arima S, et al. Atherogenic risk factors in cerebrotendinous xanthomatosis. Clin Chim Acta 1991; 200:1.</a></li><li><a class="nounderline abstract_t">Dotti MT, Mondillo S, Plewnia K, et al. Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. J Neurol 1998; 245:723.</a></li><li><a class="nounderline abstract_t">Valdivielso P, Calandra S, Durán JC, et al. Coronary heart disease in a patient with cerebrotendinous xanthomatosis. J Intern Med 2004; 255:680.</a></li><li><a class="nounderline abstract_t">Vaz FM, Bootsma AH, Kulik W, et al. A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios. J Lipid Res 2017; 58:1002.</a></li><li><a class="nounderline abstract_t">Seyama Y. Cholestanol metabolism, molecular pathology, and nutritional implications. J Med Food 2003; 6:217.</a></li><li><a class="nounderline abstract_t">Guerrera S, Stromillo ML, Mignarri A, et al. Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. J Neurol Neurosurg Psychiatry 2010; 81:1189.</a></li><li><a class="nounderline abstract_t">Mignarri A, Rossi S, Ballerini M, et al. Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. J Neurol 2011; 258:783.</a></li><li><a class="nounderline abstract_t">Arlazoroff A, Roitberg B, Werber E, et al. Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. Epilepsia 1991; 32:657.</a></li><li><a class="nounderline abstract_t">Koyama S, Kawanami T, Tanji H, et al. A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg 2012; 114:1021.</a></li><li><a class="nounderline abstract_t">Alcalay R, Wu S, Patel S, Frucht S. Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis. Mov Disord 2009; 24:1397.</a></li><li><a class="nounderline abstract_t">Posada IJ, Ramos A. Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 2011; 17:570.</a></li><li><a class="nounderline abstract_t">Rubio-Agusti I, Kojovic M, Edwards MJ, et al. Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review. Mov Disord 2012; 27:1769.</a></li><li><a class="nounderline abstract_t">Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol 2011; 18:1203.</a></li><li><a class="nounderline abstract_t">Stelten BML, van de Warrenburg BPC, Wevers RA, Verrips A. Movement disorders in cerebrotendinous xanthomatosis. Parkinsonism Relat Disord 2019; 58:12.</a></li><li><a class="nounderline abstract_t">Chen SF, Tsai NW, Chang CC, et al. Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. BMC Neurol 2011; 11:63.</a></li><li><a class="nounderline abstract_t">Verrips A, Nijeholt GJ, Barkhof F, et al. Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain 1999; 122 ( Pt 8):1589.</a></li><li><a class="nounderline abstract_t">Bartholdi D, Zumsteg D, Verrips A, et al. Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis. J Neurol 2004; 251:105.</a></li><li><a class="nounderline abstract_t">McKinnon JH, Bosch EP. Clinical reasoning: a case of treatable spastic paraparesis. Neurology 2012; 79:e50.</a></li><li><a class="nounderline abstract_t">Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.</a></li><li><a class="nounderline abstract_t">Barkhof F, Verrips A, Wesseling P, et al. Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 2000; 217:869.</a></li><li><a class="nounderline abstract_t">Berginer VM, Salen G. LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. J Neurol Sci 1994; 121:229.</a></li><li><a class="nounderline abstract_t">Mignarri A, Dotti MT, Federico A, et al. The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression. J Neurol 2017; 264:862.</a></li><li><a class="nounderline abstract_t">Federico A, Dotti MT. Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 2003; 18:633.</a></li><li><a class="nounderline abstract_t">Pitt JJ, Peters H. Screening for cerebrotendinous xanthomatosis. J Inherit Metab Dis 2015; 38:369.</a></li><li><a class="nounderline abstract_t">Cruysberg JR. Cerebrotendinous xanthomatosis: juvenile cataract and chronic diarrhea before the onset of neurologic disease. Arch Neurol 2002; 59:1975.</a></li><li><a class="nounderline abstract_t">Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 2002; 59:527.</a></li><li><a class="nounderline abstract_t">Stelten BML, van der Knaap MS, Wevers RA, Verrips A. Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis. Pediatr Neurol 2017; 73:98.</a></li><li><a class="nounderline abstract_t">Mimura Y, Kuriyama M, Tokimura Y, et al. Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. J Neurol Sci 1993; 114:227.</a></li><li><a class="nounderline abstract_t">Ito S, Kuwabara S, Sakakibara R, et al. Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis. J Neurol Sci 2003; 216:179.</a></li><li><a class="nounderline abstract_t">Dotti MT, Lütjohann D, von Bergmann K, Federico A. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis. Neurol Sci 2004; 25:185.</a></li><li><a class="nounderline abstract_t">Mondelli M, Sicurelli F, Scarpini C, et al. Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. J Neurol Sci 2001; 190:29.</a></li><li><a class="nounderline abstract_t">Federico A, Dotti MT. Cerebrotendinous xanthomatosis. Neurology 2001; 57:1743.</a></li><li><a class="nounderline abstract_t">Yahalom G, Tsabari R, Molshatzki N, et al. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 2013; 36:78.</a></li><li><a class="nounderline abstract_t">van Heijst AF, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 1998; 157:313.</a></li><li><a class="nounderline abstract_t">Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 2009; 123:143.</a></li><li><a class="nounderline abstract_t">Stelten BML, Huidekoper HH, van de Warrenburg BPC, et al. Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start. Neurology 2019; 92:e83.</a></li><li><a class="nounderline abstract_t">Huidekoper HH, Vaz FM, Verrips A, Bosch AM. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment. Eur J Pediatr 2016; 175:143.</a></li><li><a class="nounderline abstract_t">Berginer VM, Carmi R, Salen G. Pregnancy in women with cerebrotendinous xanthomatosis (CTX): high risk condition for fetus and newborn infant? Am J Med Genet 1988; 31:11.</a></li><li><a class="nounderline abstract_t">Pierre G, Setchell K, Blyth J, et al. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis 2008; 31 Suppl 2:S241.</a></li><li><a class="nounderline abstract_t">Mandia D, Chaussenot A, Besson G, et al. Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol 2019; 266:2043.</a></li><li><a class="nounderline abstract_t">Nakamura T, Matsuzawa Y, Takemura K, et al. Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis. Metabolism 1991; 40:741.</a></li><li><a class="nounderline abstract_t">Luyckx E, Eyskens F, Simons A, et al. Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. Clin Neurol Neurosurg 2014; 118:9.</a></li><li><a class="nounderline abstract_t">Verrips A, Wevers RA, Van Engelen BG, et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 1999; 48:233.</a></li><li><a class="nounderline abstract_t">Uygunoglu U, Gunduz A, Menku SF, et al. Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia. Cerebellum 2014; 13:787.</a></li><li><a class="nounderline abstract_t">Catarino CB, Vollmar C, Küpper C, et al. Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment. J Neurol 2018; 265:388.</a></li><li><a class="nounderline abstract_t">Grandas F, Martín-Moro M, Garcia-Muñozguren S, Anaya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord 2002; 17:1396.</a></li><li><a class="nounderline abstract_t">DeBarber AE, Connor WE, Pappu AS, et al. ESI-MS/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. Clin Chim Acta 2010; 411:43.</a></li><li><a class="nounderline abstract_t">Bleyle L, Huidekoper HH, Vaz FM, et al. Update on newborn dried bloodspot testing for cerebrotendinous xanthomatosis: An available high-throughput liquid-chromatography tandem mass spectrometry method. Mol Genet Metab Rep 2016; 7:11.</a></li></ol></div><div id="topicVersionRevision">Topic 1692 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : van Bogaert L, Schere H, Epstein E. Une forme cérébrale de la cholestérinose généralisée, Masson et Cie, Paris 1937.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.ncbi.nlm.nih.gov/books/NBK1409/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Federico A, Dotti MT, Gallus GN. Cerebrotendinous xanthomatosis. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1409/ (Accessed on July 18, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8514861" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019602" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019602" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888347" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Different phenotypes in identical twins with cerebrotendinous xanthomatosis: case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980151" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11137513" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2722778" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1708392" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494109" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30017468" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799805" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133792" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133792" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133792" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15131757" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1212241" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3821507" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2760539" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10775536" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9215552" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sterol 27-hydroxylase: expression in human arterial endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793579" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : High cholesterol level is essential for myelin membrane growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764421" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Brain cholesterol: long secret life behind a barrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10066446" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cholestanol induces apoptosis of cerebellar neuronal cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1763899" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Muscle mitochondrial changes in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608723" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2072121" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6504105" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3665290" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1124985" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Familial cerebrotendinous xanthomatosis. Report of a new family and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649488" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : [Peripheral neuropathy in a sporadic case of cerebrotendinous xanthomatosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11361235" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cerebrotendinous xanthomatosis in three siblings from a Chinese family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7315872" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccan origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092443" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Population screening in a Druze community: the challenge and the reward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453249" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Genetic testing in Israel: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643207" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Apparent underdiagnosis of Cerebrotendinous Xanthomatosis revealed by analysis of ~60,000 human exomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27084087" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Natural history of cerebrotendinous xanthomatosis: a paediatric disease diagnosed in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24442603" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321515" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nationwide survey on cerebrotendinous xanthomatosis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12555943" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29484516" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485361" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ocular and systemic manifestations of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15061585" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29434128" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Late-onset Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28623566" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical and molecular genetic features of cerebrotendinous xanthomatosis patients in Chinese families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8446051" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8468594" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1934506" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Atherogenic risk factors in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9808240" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15147532" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Coronary heart disease in a patient with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28314860" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A newborn screening method for cerebrotendinous xanthomatosis using bile alcohol glucuronides and metabolite ratios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585188" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cholestanol metabolism, molecular pathology, and nutritional implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20972203" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21104094" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1915172" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336472" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19373932" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Oromandibular dystonia as a complication of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21531161" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Botulinum toxin-responsive oromandibular dystonia in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23124517" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Atypical parkinsonism and cerebrotendinous xanthomatosis: report of a family with corticobasal syndrome and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21645175" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30054180" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Movement disorders in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21627786" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430841" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999499" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Spinal phenotype of cerebrotendinous xanthomatosis--a pitfall in the diagnosis of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869688" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical reasoning: a case of treatable spastic paraparesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237705" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Invited article: an MRI-based approach to the diagnosis of white matter disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110956" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158220" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324197" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572142" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234588" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Screening for cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12470193" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cerebrotendinous xanthomatosis: juvenile cataract and chronic diarrhea before the onset of neurologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11939886" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28554492" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cerebellar Disease Mimicking Cerebrotendinous Xanthomatosis: Langerhans Cell Histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445406" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607320" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15549503" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574103" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11706139" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23673909" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578968" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment and follow-up of children with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117873" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530799" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term treatment effect in cerebrotendinous xanthomatosis depends on age at treatment start.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156051" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3223491" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pregnancy in women with cerebrotendinous xanthomatosis (CTX): high risk condition for fetus and newborn infant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19125350" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31115677" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1908036" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24529221" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10024088" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25084753" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cerebrotendinous xanthomatosis: the effectiveness of high-dose piracetam for the treatment of cerebellar and sensorial ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260356" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12465096" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Early-onset parkinsonism in cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808031" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : ESI-MS/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27331003" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Update on newborn dried bloodspot testing for cerebrotendinous xanthomatosis: An available high-throughput liquid-chromatography tandem mass spectrometry method.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
